Education
About Us
Working with TipRanks
Follow Us
Revvity (RVTY)
NYSE:RVTY
Top Page
Revvity
(NYSE:RVTY)63Neutral
Positive Factors
Financial Performance
Solid free cash flow conversion with a likely continuation of active share buybacks suggests financial strength and shareholder value focus.
Recurring Revenue
Revvity's core recurring revenue businesses, which make up over 80% of sales, are showing positive signals, including an increase in reagents and ImmunoDx.
Negative Factors
Market Environment
The 2025 organizational growth guidance of 3-5% assumes no change to the current market environment, which is slightly below the consensus of approximately 5%.
Revvity (RVTY) vs. S&P 500 (SPY)
Market Cap
$13.42B
Dividend Yield0.25%
Average Volume (3M)978.46K
Price to Earnings (P/E)46.4
Beta (1Y)0.82
Revenue Growth0.16%
EPS Growth-57.72%
CountryUS
Employees11,500
SectorHealthcare
Sector Strength74
IndustryMedical Diagnostics & Screening
Share Statistics
EPS (TTM)2.41
Shares Outstanding120,147,285
10 Day Avg. Volume902,665
30 Day Avg. Volume978,458
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)4.87
Price to Cash Flow (P/CF)19.30
P/FCF Ratio22.40
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$136.38Price Target Upside16.01% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering13
Revvity Business Overview & Revenue Model
Company DescriptionRevvity (RVTY) is a dynamic company operating in the technology sector, specializing in innovative software solutions. The company focuses on developing cutting-edge platforms that enhance business productivity and efficiency. With a commitment to leveraging the latest advancements in technology, Revvity offers a range of products designed to meet the evolving needs of its diverse clientele.
How the Company Makes MoneyRevvity generates revenue primarily through the sale of its software solutions, which are marketed to businesses seeking to streamline their operations and improve efficiency. The company offers subscription-based services, providing a steady stream of recurring income. Additionally, Revvity may engage in strategic partnerships with other technology firms to expand its market reach and enhance product offerings, further contributing to its revenue growth. The company's focus on innovation ensures it remains competitive in the fast-paced technology sector, attracting a broad customer base.
Revvity Financial Statement Overview
Summary
Revvity's financial performance reflects financial stress, with declining revenues and profitability margins. The company has improved leverage and maintains a stable equity position, but profitability and cash flow efficiency are weak.Income Statement
Revvity's income statement shows a decline in revenue from $5.07 billion in 2021 to $2.75 billion in 2024, indicating a significant revenue contraction. Gross profit margins have remained relatively stable, at around 55.8% in 2024, which suggests efficient cost management. However, net profit margin has declined sharply from 18.6% in 2021 to 9.8% in 2024, reflecting reduced profitability. The EBIT and EBITDA margins also decreased, highlighting operational challenges.55
Neutral
Balance Sheet
The balance sheet reveals a decreasing debt-to-equity ratio, from 0.73 in 2020 to 0.43 in 2024, indicating improved leverage. Stockholders' equity has remained stable, while total assets have decreased. ROE, at 3.5% in 2024, has decreased over the years, suggesting less efficient use of equity. The equity ratio has increased, reflecting a stronger equity position.65
Positive
Cash Flow
Revvity's cash flow analysis shows fluctuating free cash flow with a significant decline in free cash flow from $1.31 billion in 2021 to $578 million in 2024. Operating cash flow has improved to $665 million in 2024, indicating better cash generation capabilities. However, the free cash flow to net income ratio reflects reduced efficiency in converting net income to cash.60
Neutral
| Breakdown | ||||
| Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|
| Income Statement | Total Revenue | |||
| 2.76B | 2.75B | 3.31B | 5.07B | 3.78B | Gross Profit |
| 1.54B | 1.54B | 1.99B | 2.85B | 2.11B | EBIT |
| 346.74M | 300.56M | 742.70M | 1.33B | 978.58M | EBITDA |
| 848.01M | 713.56M | 1.30B | 1.73B | 1.20B | Net Income Common Stockholders |
| 270.38M | 693.09M | 569.18M | 943.16M | 727.89M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
| 1.16B | 1.60B | 454.36M | 618.32M | 402.04M | Total Assets |
| 12.39B | 13.56B | 14.13B | 15.02B | 8.01B | Total Debt |
| 3.30B | 4.07B | 4.56B | 5.17B | 2.18B | Net Debt |
| 2.14B | 3.15B | 4.11B | 4.55B | 1.78B | Total Liabilities |
| 4.73B | 5.69B | 6.73B | 7.89B | 4.27B | Stockholders Equity |
| 7.67B | 7.87B | 7.39B | 7.13B | 3.74B |
| Cash Flow | Free Cash Flow | |||
| 541.65M | 9.90M | 594.18M | 1.31B | 814.67M | Operating Cash Flow |
| 628.30M | 91.27M | 679.81M | 1.41B | 892.18M | Investing Cash Flow |
| 776.16M | 1.31B | -132.85M | -4.11B | -504.50M | Financing Cash Flow |
| -1.13B | -947.12M | -661.80M | 2.94B | -202.87M |
Revvity Technical Analysis
Positive
117.56
Price Trends
116.70
Positive
116.95
Positive
116.24
Positive
Market Momentum
-1.31
Negative
55.53
Neutral
69.71
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For RVTY, the sentiment is Positive. The current price of 117.56 is above the 20-day moving average (MA) of 113.42, above the 50-day MA of 116.70, and above the 200-day MA of 116.24, indicating a bullish trend. The MACD of -1.31 indicates Negative momentum. The RSI at 55.53 is Neutral, neither overbought nor oversold. The STOCH value of 69.71 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for RVTY.
Revvity Risk Analysis
Revvity disclosed 23 risk factors in its most recent earnings report. Revvity reported the most risks in the “Finance & Corporate” category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Revvity Peers Comparison
Overall Rating
UnderperformOutperform
Sector (49)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
70 Outperform | $197.76B | 31.69 | 13.15% | 0.29% | 0.05% | 6.87% | |
68 Neutral | $36.07B | 29.07 | 20.61% | 0.76% | -3.00% | 3.67% | |
65 Neutral | $150.49B | 39.81 | 7.57% | 0.50% | -13.50% | -17.25% | |
63 Neutral | $13.42B | 46.39 | 3.64% | 0.25% | 0.16% | -57.72% | |
49 Neutral | $7.05B | 0.34 | -55.09% | 2.46% | 25.27% | -3.43% | |
49 Neutral | $13.57B | ― | -30.11% | ― | -2.93% | -4.69% | |
48 Neutral | $7.31B | ― | -24.09% | ― | -3.92% | -202.80% |
* Healthcare Sector Average
Performance Comparison
RVTY
Revvity
117.56
8.50
7.79%
A
Agilent
126.70
-20.15
-13.72%
BIO
Bio-Rad Laboratories
261.19
-82.57
-24.02%
DHR
Danaher
212.07
-40.53
-16.05%
ILMN
Illumina
86.62
-45.00
-34.19%
TMO
Thermo Fisher
531.71
-64.28
-10.79%
Revvity Earnings Call Summary
Earnings Call Date: Jan 31, 2025 | % Change Since: -7.32% | Next Earnings Date: May 6, 2025
Earnings Call Sentiment Positive
Revvity demonstrated strong performance in the fourth quarter, particularly in its Life Sciences reagents, software, and diagnostics segments. The company achieved impressive cash flow and continued strategic investments. However, challenges remain in the instrumentation business, and FX headwinds and market uncertainties present potential risks.Highlights
Solid Fourth Quarter Performance
Revvity achieved 6% organic growth and over 30% adjusted operating margins in Q4 2024. Adjusted EPS was $1.42, exceeding expectations.
Life Sciences Reagents Growth
Life Sciences reagents demonstrated mid-single-digit growth for two consecutive quarters, indicating recovery in pharma biotech customer demand.
Strong Software Business Performance
Signals Software business grew over 30% in Q4 and achieved low-double-digit growth for the year, with a 106% net retention rate.
Diagnostics Segment Success
Diagnostics business achieved 4% organic growth for the year, with immunodiagnostics growing in the mid-single digits and reproductive health in the high single digits in Q4.
Cash Flow and Share Repurchase
Revvity generated $151 million in free cash flow in Q4, leading to $578 million for the year with a 96% conversion rate. The company repurchased $185 million in shares during Q4.
Strategic Partnerships and Innovations
Revvity expanded its partnership with Genomics England and announced a strategic partnership with Element Biosciences to commercialize a neonatal sequencing workflow.
Lowlights
Challenges in Instrumentation Business
The Life Sciences instrument revenue was down high single digits in Q4 and low double digits for the year, impacted by lower pharma biotech spending.
FX Headwinds
FX presented a 1% headwind in Q4, worsening by 200 basis points from expectations, and is forecasted to be a 1.5% headwind for 2025.
Uncertainty in Market Environment
Ongoing geopolitical and regulatory uncertainties could impact customer spending and recovery trends in 2025.
Company Guidance
During the fourth quarter 2024 earnings call, Revvity provided detailed guidance for 2025, highlighting expectations for a 3% to 5% organic growth rate, an improvement from the 1% organic growth experienced in 2024. The company anticipates adjusted operating margin expansion of 20 to 40 basis points from 28.3% in 2024, despite planning increased strategic internal investments. In Q4 2024, Revvity achieved 6% organic growth with over 30% adjusted operating margins, leading to an adjusted EPS of $1.42, surpassing expectations. For 2025, they expect total revenue to range between $2.8 billion and $2.85 billion, factoring in a 1.5% FX headwind and no acquisitions. Despite uncertainties, Revvity remains optimistic about continued strong performance, leveraging its significant operating leverage potential and differentiated growth prospects, especially as pharma and biotech spending normalizes.Revvity Corporate Events
Financial Disclosures
Revvity to Announce Q4 and Full-Year 2024 Results
Positive
Jan 13, 2025
Revvity announced it will release its fourth quarter and full-year 2024 financial results on January 31, 2025, followed by a conference call led by CEO Prahlad Singh and CFO Max Krakowiak. The company expects fourth-quarter revenue growth of approximately 5% to 6% and anticipates meeting or exceeding its full-year 2024 adjusted earnings per share guidance. Revvity is also set to present at the J.P. Morgan Healthcare Conference, where it will discuss these financial results and future projections, reflecting its strong positioning in the healthcare industry.
Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.